Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: May 5, 2010

Premium

Illumina last week announced the appointments of Elizabeth Brady as VP of global supply chain, and Emily Winn-Deen as VP of diagnostics development.

Brady will report to William Bonnar, senior VP of Illumina's operations. Prior to joining Illumina, Brady was VP of global supply chain at Boston Scientific's cardiac rhythm management division.

Winn-Deen will report to Gregory Heath, Illumina's VP of diagnostics. She previously served as president of the consulting practice Rx Dx Advisors, and held leadership positions at Cepheid.

As incentives to join the company, Brady was granted the option to purchase 120,000 shares of Illumina's common stock and Winn-Deen received an option to purchase 112,000 shares. The grant date for the option to Brady is May 3, and April 26 for Winn-Deen.


Canada-based molecular diagnostics firm GeneNews announced the appointment of Leslie Auld as its new chief financial officer and treasurer, effective May 3.

Prior to joining GeneNews, Auld held various leadership positions at PricewaterhouseCoopers, Helix BioPharma, Luminex Diagnostics, and Attwell Capital.

Auld succeeds Sonny Young who since January has held the interim position of VP of finance and treasurer. Young will continue to work for GeneNews as a consultant.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.